Back to journals
Academic JournalOpen Access

Frontiers in Psychiatry

85 Papers Indexed in Blossom

Data updated

Publication Landscape

How the 85 psychedelic papers Blossom tracks from Frontiers in Psychiatry line up by year, topic and compound. This is the journal's psychedelic-research output in Blossom's records as of July 2026; its full catalogue is much larger.

How much psychedelic research does Frontiers in Psychiatry carry?

Sourced

Tracked papers by publication year. Click a year for the running total.

22papers published in 2023

+5% vs 2022

73 published by 2023

Browse papers→

Don't read as the journal's total output: only the 85 of 85 tracked psychedelic papers from Frontiers in Psychiatry with a recorded publication date are counted, and Blossom tracks only psychedelic-relevant papers, so the full catalogue is much larger. The current year is still filling in.

What does Frontiers in Psychiatry publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Anxiety Disorders
48
Depressive Disorders
45
PTSD
25
Addiction & Substance Use
23
Safety & Risk Management
11
Personality & Trait Factors
11
Set & Setting
10
Suicidality
10
Other
93

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not the journal's full catalogue.

Which compounds does Frontiers in Psychiatry cover?

Sourced

Tracked papers per compound. Orange marks the most-covered compound.

Psilocybin
25
MDMA
20
Ketamine
13
LSD
11
Ayahuasca
10
DMT
5
5-MeO-DMT
4
Mescaline
4
Other
3

Don't read shares as adding to 100%: a paper studying several compounds counts once per compound, and placebo comparator arms are not shown. These are the psychedelic-relevant papers Blossom tracks.

Research Footprint

Frontiers in Psychiatry has 85 tracked papers indexed in Blossom (2018–2026) from 459 authors, most often covering Psilocybin, MDMA and Ketamine, across Anxiety Disorders, Depressive Disorders and PTSD.

Published Papers

Open Accessindividual

Real-world outcomes of intranasal esketamine and intravenous ketamine induction therapy for treatment-resistant depression in a community clinic: a retrospective cohort study

This retrospective cohort study (n=63) compared induction treatment with intranasal esketamine and intravenous ketamine for treatment-resistant depression in a community clinic and found large reductions in depression scores in both groups. There were no serious adverse events, and the two treatments had similar short-term outcomes, although the study was too small to show whether one was better than the other.

Published
Journal
Frontiers in Psychiatry
Authors
Bellanti, P. A., Lewis, J., Seifferth, B., Adams, D. Z.
Open Accessindividual

Navigating ‘k-land’: a qualitative exploration of participants’ experiences of ketamine-assisted psychotherapy for methamphetamine use disorder

This qualitative study (n=14) explored how people with methamphetamine use disorder experienced ketamine-assisted psychotherapy and found that it was generally acceptable in a supportive setting. Participants described ketamine as creating a temporary state of reduced emotional and mental reactivity that seemed to help them engage with therapy, but changes in methamphetamine use were variable and depended on ongoing support and motivation.

Published
Journal
Frontiers in Psychiatry
Authors
Fletcher, K., Ezard, N., Siefried, K. J., van der Helder, S., Freestone, J., Brett, J., May, R., Acheson, L., Clifford, B.
Open Accessindividual

Case Report: Repeated low doses of psilocybin reduce perceived symptom severity but fail to restore cognitive flexibility in a case of severe obsessive-compulsive disorder: an observational case study of identical twins

This observational case study of identical twins found that repeated low doses of psilocybin in one twin with severe obsessive-compulsive disorder (OCD) were linked to lower perceived symptom severity and better emotional well-being. However, the affected twin still showed impaired cognitive flexibility compared with the unaffected twin.

Published
Journal
Frontiers in Psychiatry
Authors
Drange, S., Cohen, J., Johansen, S. S., Dunkley, B., Palner, M.
Open Accessindividual

Synergies in psychedelic-assisted therapy: a qualitative interview study of psychotherapeutic processes

This qualitative study (n=7) interviewed Swiss therapists about psychedelic-assisted therapy and found they saw psychedelics as working alongside psychotherapy rather than replacing it. Therapists described a synergy that could strengthen trust, depth and meaningful therapeutic experiences within long-term treatment.

Published
Journal
Frontiers in Psychiatry
Authors
Stellmacher, J., Schmidt, C., Aicher, H. D., Eichel, K., Brakemeier, E. L., Herwig, U.
Open Accessindividual

Inaugural year of regulated psilocybin services in Oregon: safety, motivations, and utilization

This descriptive analysis of statewide data from Oregon’s regulated psilocybin services in 2025 found 5,935 clients in 5,375 sessions, mostly midlife adults, with substantial use by women and LGBTQ+ people but limited racial diversity. Acute behavioural and medical adverse events were rare, while many clients came from outside Oregon.

Published
Journal
Frontiers in Psychiatry
Authors
Yu, F., Tafur, J., Moreno, F., Dahmer, S.
Open Accessindividual

Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis

Qualitative interviews with 12 participants from a randomized, placebo‑controlled single‑dose psilocybin trial for treatment‑refractory OCD showed that set and setting strongly shaped acute (often partial) perceptual, emotional and metacognitive experiences, which were followed by post‑dosing changes in OCD symptoms, perceptions and behavioural/metacognitive processes. These changes mapped onto putative mechanisms of ERP and ACT, suggesting hypotheses for further study and potential value in integrating psilocybin with structured psychotherapy for OCD.

Published
Journal
Frontiers in Psychiatry
Authors
Ching, T. H. W., Stahnke, B., Shnayder, S., Agin-Liebes, G., Adams, T. G., Amoroso, L., Baiz, O., Belser, A., Bohner, C., Burke, M., D’Amico, E., DePalmer, G., Eilbott, J., Fram, G., Grazioplene, R., Hokanson, J., Jankovsky, A., Kichuk, S. A., Martins, B., Purohit, P., Schaer, H., Sierra, Y. P., Witherow, C., Pittenger, C., Kelmendi, B.

Quick Facts

Papers Indexed
85
h-Index
134
Open Access
Yes
Publisher
Frontiers Media
Country
Switzerland
Website
Visit